Living Donor Liver Transplants: Better Outcomes for Children

Published on 
September 21, 2021

Living-Donor-Liver-Transplant-Press-Release.jpg

In a worldwide pediatric study, researchers from Children’s Hospital Los Angeles show the clear benefit of using living donor liver tissue for transplants.


In the United States alone, 500 children will need a liver transplant this year. While liver tissue can come from living or deceased donors, no studies have demonstrated which of these methods leads to better outcomes for children. In a new publication, researchers at Children’s Hospital Los Angeles pooled published results from over 8,000 pediatric patients across four continents. The data reveal that children who receive living donor liver tissue for transplants are far less likely to experience serious complications like organ rejection.

Thanks to advances in modern medicine and the unique ability of the liver to regenerate, healthy individuals can donate a portion of their liver to a patient in need. Many countries around the world have moved to exclusively performing living donor liver transplants, while in the United States, only 8% of liver transplants are from living donors.

But some hospitals—like Children’s Hospital Los Angeles—have a growing living donor program. “We perform about 25 to 30 liver transplants a year,” says Rohit Kohli, MBBS, MS, Chief of the Division of Gastroenterology. About a third of these transplants, he says, are from living donors.

“We have published large-scale studies showing the benefits of living donor liver transplantation in adults,” says Juliet Emamaullee, MD, PhD, Research Director in the Division of Abdominal Organ Transplantation. “And we’ve observed the benefits in kids too. But we really wanted to evaluate it systematically, to provide evidence from around the world to back up what we’ve seen.”

The team began by poring through more than 2,500 studies. From this, they distilled relevant studies, compiling data from 8,000 pediatric patients who had received either living or deceased donor livers. Results from a year after the procedure show that children who received living donor liver transplants had nearly twice the survival rate while the risk of organ rejection was reduced by nearly half.

The use of living donor tissue for liver transplants has several benefits, which may contribute to the striking difference in outcomes. Living donation often shortens the wait time for a patient in need because they do not need to wait for an appropriately sized deceased organ donor, which can be particularly difficult for infants and toddlers, who make up over 50% of pediatric liver transplants. But perhaps the biggest advantage is that patients may be healthier at the time of their procedure.

“When a liver becomes available, the basic rule is that it goes to the sickest child,” says Dr. Kohli. “And that makes sense. We don’t want any child dying on the waiting list.” But, unfortunately, this means that children can wait years before receiving a needed transplant. It also means that they may be very ill by the time an organ becomes available. This could affect how well a child does once he or she receives a new liver.

“These results are important and relevant for families,” says Dr. Emamaullee. “Not all children are at a center that offers living donor liver transplant. Now we have the data to suggest that kids really should be offered this option. Families should have the chance to donate to their children rather than having to wait until an organ donor comes along.”

Meaningful studies like these often come from many people working together: clinicians, scientists and even students. “We had undergraduate researchers, medical students, a resident and collaborators at a large Canadian center helping to pool all these data together and analyze them in a meaningful way,” says Dr. Emamaullee.

“As a pediatrician, I want children getting the best chance possible,” says Dr. Kohli. “Studies like these inform our care. They show us how to do the best possible job for our kids.”

The work was supported by the National Cancer Institute (K08 CA245220-01). Additional authors on the paper are: Arianna Barbetta, MD; Chanté Butler, BS; Sarah Barhouma; Rachel Hogen, MD; Brittany Rocque, MD, MS; Cameron Goldbeck, MS, Hannah Schillperoort, MLIS; Yong K. Kwon, MD; all of the University of Southern California and Children’s Hospital Los Angeles. From The University of Alberta, authors include: Glenda Meeberg, MS, and A.M. James Shapiro, MD, PhD. The Pediatric Liver transplant program at CHLA is led by Yuri Genyk, MD, and Beth Carter, MD.


About Children's Hospital Los Angeles

Founded in 1901, Children's Hospital Los Angeles is the largest provider of care for children in Los Angeles County. Families travel from all 50 states and more than 90 countries so that their children can receive the very best care. The hospital’s clinical teams treat patients ranging in age from newborn infants to young adults for everything from well-child visits to organ transplantation. It is ranked the top children’s hospital in California as well as in the Pacific region, and fifth in the nation for clinical excellence by U.S. News & World Report in its prestigious Honor Roll of Best Children’s Hospitals. Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC through an affiliation dating from 1932. It is home to the largest pediatric residency training program at a freestanding children’s hospital of its kind in the western United States. Among top 10 children’s hospitals for National Institutes of Health funding, The Saban Research Institute of Children’s Hospital Los Angeles leads the field in innovative bench-to-bedside basic, translational and clinical research conducted in pediatrics. To learn more, follow us on Facebook, Instagram, LinkedIn, YouTube and Twitter, and visit our blog at CHLA.org/blog.

Categories: